Third and last session of #psychedelics @NIH ๐บ๐ฒ workshop starting now, looking at how to optimize clinical trials design and how to get these treatments approved ๐งต
Starting with Ido @hartogsohn ๐ฎ๐ฑ on psychedelic set and setting theory 
Important Q โ
Do we have an (excessively) costly and complicated drug regulation apparatus?
Do we have an (excessively) costly and complicated drug regulation apparatus?
Now my friend @DrSureshMuthu, lead author of one of the most important papers of 2021 tandfonline.com/doi/full/10.10โฆ, on how to improve clinical trial designs ๐ค
The unblinding problem has been drawn โ๏ธ
High unblinding in psychedelic trials
A paradox? ๐
Possible treatment designs
Many biases. What was controlled in the end?
Great work and excellent talk @DrSureshMuthu ๐ณ๐ฟ
Next @appelbap on Ethical issues and challenges for research and clinical use
Sexual abuse issues โ ๏ธ
Steering the future through ethics
Next is Javier Muniz from @US_FDA ๐บ๐ฒ
Unique challenges
Psychotherapy and labeling
Important recommendations to reduce bias ๐ง
Last panel now facing some hard questions:
How do we regulate this in safe and beneficial ways?
What else is needed and how will it unfold?
How do we regulate this in safe and beneficial ways?
What else is needed and how will it unfold?
@threadreaderapp compile please
โข โข โข
Missing some Tweet in this thread? You can try to
force a refresh
ใ
